This morning the Relief Therapeutics (OTCMKTS:RLFTF) stock has jumped as much as 9% after the company announced that an Emergency Use Authorization request has been submitted for its product Zyesami to the United States Food and Drug Administration.
The application had been filed by Relief along with its partner NRx Pharmaceuticals. Zyesami is meant for treating those critically ill COVID 19 patients who might be suffering from severe respiratory problems.
The company had earlier announced that patients treated with Zyesami resulted in significant improvement in the conditions of patients and also helped with correcting respiratory failure. The publication of the dual news has brought in a wave of optimism for the Relief Therapeutics stock and it now remains to be seen if the stock can continued to hold on to its momentum. The entirety of the data is going to be published by the two companies in a peer reviewed journal soon.
Market Action:
At the time of writing, RLFTF stock gained 3.35% to $0.235. The stock has seen a total volume of 2.91 million shares, compared to its average volume of 7.30 million shares.
 Stock Gains Further: Will The Momentum Continue?){kind=link}